SCHEMBL512637

SCHEMBL512637

CCOC(=O)Cc1ccc(Cl)cc1F

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
HPGD P15428 1/20 0.46
ALDH1A1 P00352 3/20 0.45
KDM4E B2RXH2 1/20 0.45
HTT P42858 1/20 0.45
MAPT P10636 2/20 0.45
TDP1 Q9NUW8 1/20 0.43
RAB9A P51151 1/20 0.43
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
PKM P14618 1/20 0.41
GAA P10253 1/20 0.41
ERCC1 P07992 1/20 0.41
ERCC4 Q92889 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29924605 1.00 KMT2A (0.46) KMT2AMEN1HPGDALDH1A1KDM4E
SCHEMBL18641931 0.86 KMT2A (0.57) KMT2AMEN1HPGDALDH1A1KDM4E
SCHEMBL16731569 0.85 KMT2A (0.49) KMT2AMEN1HPGDALDH1A1KDM4E
SCHEMBL8361248 0.85 CYP4F2 (0.50) KMT2AMEN1HPGDALDH1A1KDM4E
SCHEMBL31441299 0.84 KMT2A (0.57) KMT2AMEN1HPGDALDH1A1KDM4E
SCHEMBL1525187 0.84 ERCC1 (0.46) KMT2AMEN1ALDH1A1KDM4EHTT
SCHEMBL706766 0.84 ALDH1A1 (0.51) KMT2AMEN1HPGDALDH1A1HTT
SCHEMBL707398 0.84 KMT2A (0.57) KMT2AMEN1HPGDALDH1A1KDM4E
SCHEMBL10258195 0.84 NLRP3 (0.43) KMT2AALDH1A1TDP1CYP2C9PKM
SCHEMBL15011980 0.83 EGFR (0.52) KMT2AMEN1ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062401-A1 METHODS OF TREATING NEUROLOGICAL DISORDERS NEUMORA THERAPEUTICS INC (US) 2026-03-05 US disclosed
US-12371414-B2 Methods of treating neurological disorders Neumora Therapeutics, Inc. (US) 2025-07-29 US disclosed
US-20240294492-A1 METHODS OF TREATING NEUROLOGICAL DISORDERS Neumora Therapeutics, Inc. 2024-09-05 US disclosed
US-20240246928-A1 METHODS OF TREATING NEUROLOGICAL DISORDERS Neumora Therapeutics, Inc. 2024-07-25 US disclosed
WO-2024119067-A1 METHODS OF TREATING NEUROLOGICAL DISORDERS Neumora Therapeutics, Inc. (US) 2024-06-06 WO disclosed
US-11993580-B1 Methods of treating neurological disorders Neumora Therapeutics, Inc. (US) 2024-05-28 US disclosed
CN-117177970-A Polycyclic derivative regulator, preparation method and application thereof 上海翰森生物医药科技有限公司 2023-12-05 CN disclosed
US-20230219978-A1 COMPOUND HAVING MACROCYCLIC STRUCTURE AND USE THEREOF SCINNOHUB PHARMACEUTICAL CO., LTD (CN) 2023-07-13 US disclosed
US-20230219978-A1 COMPOUND HAVING MACROCYCLIC STRUCTURE AND USE THEREOF SCINNOHUB PHARMACEUTICAL CO., LTD (CN) 2023-07-13 US disclosed
US-20230219978-A1 COMPOUND HAVING MACROCYCLIC STRUCTURE AND USE THEREOF SCINNOHUB PHARMACEUTICAL CO., LTD (CN) 2023-07-13 US disclosed
EP-0885885-B1 PYRIDONE DERIVATIVES AND HERBICIDES KUMIAI CHEMICAL INDUSTRY CO (JP) 2006-01-04 EP disclosed
US-6472348-B1 Pyridone derivatives and herbicides KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) 2002-10-29 US disclosed
US-6265349-B1 Pyridone derivatives and herbicides KUMIAI CHEMICAL INDUSTRY CO., LTD (JP) 2001-07-24 US disclosed
US-6242634-B1 OF HERBICIDES, HALOPHENYL COMPOUNDS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-06-05 US disclosed
US-6100257-A 2-HALOALKYL,3-(HALOALKYL, ALKENYL, OR ALKYNYL),5-(SUBSTITUTED PHENYL OR HETEROCYCLE),6-ALKYL-PYRIMIDIN-4-ONE COMPOUNDS OF GIVEN STRUCTURE; USE AS HERBICIDES SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2000-08-08 US disclosed
US-6048823-A Pyridone derivatives and herbicides KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) 2000-04-11 US disclosed
EP-0885885-A1 PYRIDONE DERIVATIVES AND HERBICIDES KumaiI Chemical Industry Co., Ltd. (JP) 1998-12-23 EP disclosed
CN-1198742-A Pyrimidin-4-one derivatives, their use as herbicides, intermediates for their production and process for producing these compounds SUMITOMO CHEMICAL CO (JP) 1998-11-11 CN disclosed
EP-0850229-A1 PYRIMIDIN-4-ONE DERIVATIVES, THEIR USE AS HERBICIDES, INTERMEDIATES FOR THEIR PRODUCTION AND PROCESSES FOR PRODUCING THESE COMPOUNDS SUMITOMO CHEMICAL COMPANY LIMITED (JP) 1998-07-01 EP disclosed
WO-1997006150-A1 PYRIMIDIN-4-ONE DERIVATIVES, THEIR USE AS HERBICIDES, INTERMEDIATES FOR THEIR PRODUCTION AND PROCESSES FOR PRODUCING THESE COMPOUNDS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1997-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11993580-B1 Methods of treating neurological disorders SMN1; SMN2, CLN6, PMP22 KMT2A 3345/4885MEN1 1283/4885HPGD 851/4885
US-20240246928-A1 METHODS OF TREATING NEUROLOGICAL DISORDERS SMN1; SMN2, CLN6, PMP22 KMT2A 3345/4885MEN1 1283/4885HPGD 851/4885
US-20260062401-A1 METHODS OF TREATING NEUROLOGICAL DISORDERS HCN2, HCN3, HCN1 KMT2A 2170/4885MEN1 911/4885HPGD 3761/4885
US-20230219978-A1 COMPOUND HAVING MACROCYCLIC STRUCTURE AND USE THEREOF BTK, SRC, YES1 KMT2A 1866/4885MEN1 306/4885HPGD 4855/4885
US-20240294492-A1 METHODS OF TREATING NEUROLOGICAL DISORDERS SMN1; SMN2, CLN6, PMP22 KMT2A 3283/4885MEN1 1319/4885HPGD 823/4885
US-12371414-B2 Methods of treating neurological disorders SMN1; SMN2, CLN6, PMP22 KMT2A 3345/4885MEN1 1283/4885HPGD 851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.